1. Home
  2. TRVI vs ETWO Comparison

TRVI vs ETWO Comparison

Compare TRVI & ETWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • ETWO
  • Stock Information
  • Founded
  • TRVI 2011
  • ETWO 2000
  • Country
  • TRVI United States
  • ETWO United States
  • Employees
  • TRVI N/A
  • ETWO N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • ETWO EDP Services
  • Sector
  • TRVI Health Care
  • ETWO Technology
  • Exchange
  • TRVI Nasdaq
  • ETWO Nasdaq
  • Market Cap
  • TRVI 629.8M
  • ETWO 663.4M
  • IPO Year
  • TRVI 2019
  • ETWO N/A
  • Fundamental
  • Price
  • TRVI $5.76
  • ETWO $3.21
  • Analyst Decision
  • TRVI Strong Buy
  • ETWO Sell
  • Analyst Count
  • TRVI 8
  • ETWO 4
  • Target Price
  • TRVI $19.31
  • ETWO $2.78
  • AVG Volume (30 Days)
  • TRVI 1.0M
  • ETWO 15.8M
  • Earning Date
  • TRVI 05-08-2025
  • ETWO 07-09-2025
  • Dividend Yield
  • TRVI N/A
  • ETWO N/A
  • EPS Growth
  • TRVI N/A
  • ETWO N/A
  • EPS
  • TRVI N/A
  • ETWO N/A
  • Revenue
  • TRVI N/A
  • ETWO $607,688,000.00
  • Revenue This Year
  • TRVI N/A
  • ETWO $1.98
  • Revenue Next Year
  • TRVI N/A
  • ETWO $2.71
  • P/E Ratio
  • TRVI N/A
  • ETWO N/A
  • Revenue Growth
  • TRVI N/A
  • ETWO N/A
  • 52 Week Low
  • TRVI $2.30
  • ETWO $1.75
  • 52 Week High
  • TRVI $7.39
  • ETWO $4.82
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 56.14
  • ETWO 73.54
  • Support Level
  • TRVI $6.08
  • ETWO $3.19
  • Resistance Level
  • TRVI $6.47
  • ETWO $3.28
  • Average True Range (ATR)
  • TRVI 0.39
  • ETWO 0.07
  • MACD
  • TRVI -0.00
  • ETWO 0.05
  • Stochastic Oscillator
  • TRVI 45.06
  • ETWO 90.41

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About ETWO E2open Parent Holdings Inc.Class A

E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.

Share on Social Networks: